Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Carfilzomib Maintenance Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols

Study:

An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib Maintenance Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols

Rationale:

n/a

Purpose:

This is a multi-center, open-label, Phase 2 study of carfilzomib to monitor the safety and efficacy of a maintenance therapy schedule for subjects who previously completed a primary carfilzomib treatment study. Only subjects who have achieved and maintained a response of at least stable disease (SD) through to completion of the prior carfilzomib study will be eligible for the current maintenance study.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Multiple Myeloma Drug: Carfilzomib Phase 2

Verified by Onyx Therapeutics, Inc. January, 2013

Sponsored by: Onyx Therapeutics, Inc.
Information provided by: Onyx Pharmaceuticals
ClinicalTrials.gov identifier: NCT00884312

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.